Natixis Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Natixis Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-31,088	Closed	-$218K	–	1339
2021 Q1	$218K	Buy	+31,088	New	+$208K	﹤0.01%	1250

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Natixis Advisors's CLVS Position: Q2 2021 in Review

Natixis Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2021, closing a stake of 31,088 shares — an estimated $218K sold.

Natixis Advisors first reported a position in CLVS in Q1 2021 and held it in 1 quarter. The position peaked at $218K in Q1 2021. 160 funds tracked by Wall St. Rank hold CLVS as of Q2 2021.

Natixis Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2021 after selling out during the quarter.
Natixis Advisors sold 31,088 Clovis Oncology, Inc. shares in Q2 2021, an estimated $218K.
Natixis Advisors first reported a position in Clovis Oncology, Inc. in Q1 2021 and held it in 1 quarter.
Natixis Advisors's Clovis Oncology, Inc. position peaked at $218K in Q1 2021.
160 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2021.

Based on Natixis Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.